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There has certainly been a progression in the approach to locally 
advanced non-small cell lung cancer over the last two decades. Until 
the 1980s, radiation therapy alone had been the standard of care for 
locally advanced NSCLC despite the dismal survival data. During the 
early 1990s, results of multiple randomized phase III studies shifted the 
standard toward concurrent chemoradiation therapy. 
The mechanism of chemotherapeutic radiosensitization is thought to be 
direct inhibition of radiation-induced damage repair; elimination of ra-
dioresistant, chemosensitive clones; and/or suppression of inter-fraction 
tumor repopulation. Concurrent chemoradiation addresses both distant 
and locoregional disease simultaneously. The two modalities should act 
synergistically on tumor clonogens susceptible to both modality and in 
a complementary fashion on locoregional clonogens that are suscep-
tible to only one of the modalities. A number of phase III randomized 
trials have shown a statistically signiﬁcant improvement in clinical 
outcomes, including survival, with the concurrent approach. However, 
this aggressive strategy has also led to an increase in the incidence and 
severity of treatment-related toxicities.
These innovations in treatment now begin to cooperate with improve-
ments in the imaging of cancers like PET scanning and with the im-
provements in computers and automation that are allowing us to deliver 
radiation in a more conformal fashion than before to reduce toxicity 
while improving tumor control. The implication of these new technolo-
gies in treating lung cancers is really quite profound. New treatment 
planning systems allow for the delivery of more targeted radiation with 
multiple, non-traditional ﬁeld arrangements when needed to protect 
normal structures. Areas of atelectatic lung remain a challenge for the 
radition oncologist to be able to adequately deﬁne the target volume. 
However, incorporation of the physiologic data provided by PET scan-
ning may not only allow physicans to spare the collapsed lung but may 
allow them to deliver higher doses of radiation to more biologically 
active and presumably more aggressive areas of tumors as well. 
Advances in radiation therapy (RT) techniques, chemotherapeutic 
regimens, and different combined-modality approaches have yielded a 
modest impact on the prognosis of patients with advanced lung cancer. 
But the median survival for locally advanced NSCSL patients is only 
18-24 month at best. There is clearly a need for additional strategies. 
Recent discoveries in molecular biology have identiﬁed a number of 
molecular determinants that may be responsible for resistance of cancer 
cells to radiation or other cytotoxic agents, and as such may serve as tar-
gets for augmentation of radio- or chemo-response. Among these deter-
minants are epidermal growth factor receptor (EGFR), Anti Angiogeneis 
agents, mutated ras, angiogenic molecules, and various other molecules 
that regulate different steps in their signal transduction pathways.
Incorporating newer biologic agents into chemoradiotherapy is criti-
cal to further improve outcomes in this setting. One strategy should 
improve therapeutic outcomes by blocking receptors and pathways that 
help tumor cells survive radiation and repair damage without increas-
ing normal tissue toxicity. In this meeting we will review the current 
research challenges in incorporating these agents into radiotherapy 
and chemoradiotherapy and preliminary data in patients with locally 
advanced NSCLC.
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Since the TNM system has been applied to lung cancer, patients have 
been paradigmatically subdivided into two subcategories, according 
to surgical possibilities. The surgical landmark was deﬁned precisely 
between stages III A and B, since T3 and/or N2 tumors are world-
widely considered as ﬁt for resection, while T4 and/or N3 are generally 
unresectable [1]. Actually non-small cell lung cancers (NSCLC) should 
be subdivided in three subgroups: 1) patients who could be cured by 
surgery alone, some of them able to beneﬁt from adjuvant strategy; 2) 
patients with so-called marginally resectable locally advanced tumors, 
in which surgical resection alone is generally unable to achieve a 
long-term survival; 3) patients with advanced disease, deﬁnitively not 
amenable to surgery [2]. 
Stage IIIA
Theoretically resectable, stage IIIa disease actually includes a high pro-
portion of non-resectable tumors, particularly because of nodal disease. 
These locally advanced lung cancers have a poor prognosis, related to 
their high potential for distant metastases. According to the hypothesis 
that the tumor debulking induced by neo-adjuvant treatments could 
render resectable some locally advanced NSCLC tumors in selected 
patients, chemotherapy, or chemoradiotherapy, was proposed as induc-
tion pre-operative strategy in stages IIIA patients. A large european 
randomized study comparing induction chemotherapy with primary 
surgery failed to demonstrate the superiority of neoadjuvant treatment 
in stage IIIA category [3]. Contrarily a retrospective study of more 
than 700 resected N2 non-small cell lung cancers showed that those 
preoperatively treated patients achieved a signiﬁcantly better survival 
than patients who did not receive induction chemotherapy [4]. A 
North American Intergroup randomized study, attempted to assess the 
relevance of surgical resection after induction chemo-radiotherapy in 
stage IIIA NSCLC with N2 disease [5]. This trial explored the surgi-
cal question on a very homogeneous group of T1 to T3/N2 disease. 
Preliminary results of INT 0139 showed better survival (38% and 33% 
at 3 years in the surgical and non-surgical arms, respectively) than was 
observed in previous phase II trials (26% for N2 disease at 3 years in 
SWOG 8805[6]). Interstingly, half of the patients (46%) were down-
staged to N0, and for those patients, median survival was 37 months. 
These results emphasize the hypothesis that the absence of tumor in 
the mediastinal nodes at surgery is the strongest predictor of long-term 
survival, as it was previously reported in other studies [4,6,7,8]. A 
prospective approach for future clinical practice could suggest conduct-
ing surgery only on patients who respond at the mediastinal level after 
induction treatment. Another randomized trial in Europe compared 
surgical resection to radiotherapy after induction chemotherapy in stage 
IIIA-N2 non-small cell lung cancer [9]. In this study surgical resection 
did not improve survival in comparison to radiotherapy. Nevertheless, 
an unplanned subgroup analysis performed in the surgery-arm showed 
that mediastinal clearance was a statistically signiﬁcant factor. 
